Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Significant Decrease in Short Interest

26 Dec 2025, 07:30 by Teresa Graham · The Cerbat Gem

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totaling 246,333 shares, a decline of 59.5% from the November 30th total of 608,275 shares. Based on an average daily volume of 826,473 shares, the short-interest ratio is presently 0.3 days. Approximately 0.3% of the company’s stock are sold short. Approximately 0.3% of the company’s stock are sold short. Based on an average daily volume of 826,473 shares, the short-interest ratio is presently 0.3 days.

Century Therapeutics Price Performance

IPSC opened at $1.03 on Friday. Century Therapeutics has a 1 year low of $0.34 and a 1 year high of $1.19. The company has a market capitalization of $90.11 million, a price-to-earnings ratio of -3.22 and a beta of 1.80. The firm’s fifty day moving average price is $0.60 and its two-hundred day moving average price is $0.57.

Century Therapeutics (NASDAQ:IPSC – Get Free Report) last announced its earnings results on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.07. Century Therapeutics had a negative net margin of 19.10% and a negative return on equity of 10.01%. As a group, equities analysts anticipate that Century Therapeutics will post -1.61 EPS for the current year.

Insider Buying and Selling at Century Therapeutics

In related news, CEO Brent Pfeiffenberger acquired 52,000 shares of the business’s stock in a transaction dated Friday, December 12th. The shares were bought at an average price of $0.58 per share, with a total value of $30,160.00. Following the transaction, the chief executive officer directly owned 3,322,990 shares of the company’s stock, valued at $1,927,334.20. This trade represents a 1.59% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 65,987 shares of company stock worth $29,798 in the last quarter. 4.37% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Century Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of IPSC. Citadel Advisors LLC increased its position in shares of Century Therapeutics by 64.1% during the third quarter. Citadel Advisors LLC now owns 360,825 shares of the company’s stock valued at $180,000 after acquiring an additional 140,891 shares during the last quarter. Two Sigma Investments LP grew its stake in Century Therapeutics by 59.2% in the 3rd quarter. Two Sigma Investments LP now owns 911,446 shares of the company’s stock valued at $454,000 after purchasing an additional 338,902 shares during the period. Squarepoint Ops LLC grew its stake in Century Therapeutics by 483.1% in the 3rd quarter. Squarepoint Ops LLC now owns 236,053 shares of the company’s stock valued at $118,000 after purchasing an additional 195,573 shares during the period. GSA Capital Partners LLP increased its position in shares of Century Therapeutics by 29.3% during the 3rd quarter. GSA Capital Partners LLP now owns 603,479 shares of the company’s stock valued at $301,000 after purchasing an additional 136,873 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Century Therapeutics during the 2nd quarter worth $248,000. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Analyst Upgrades and Downgrades

IPSC has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Century Therapeutics in a report on Wednesday, October 8th. Leerink Partnrs cut Century Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 17th. Wall Street Zen downgraded shares of Century Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 20th. Finally, Leerink Partners reissued a “market perform” rating and set a $2.00 target price (down from $7.00) on shares of Century Therapeutics in a research report on Monday, November 17th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $3.40.

Check Out Our Latest Stock Analysis on Century Therapeutics

About Century Therapeutics

(Get Free Report)

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.